Johnson & Johnson today announced new data from the Phase 3 Vivacity-MG3 study and ongoing open label extension (OLE) in a broad population of antibody-positive (including anti-AChR+ b and anti-MuSK+ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results